Use of chimeric antigen receptor modified cells to treat cancer
AssigneeInnovative Cellular Therapeutics, Inc.
InventorsLei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
Claims15
An isolated nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain binds to Guanylate cyclase 2C (GUCY2C), and wherein the CAR comprises amino acid sequence SEQ ID NO:
- 40.
Dependencies are inferred from the claim text.